Work

Does cefiderocol heteroresistance explain the discrepancy between the APEKS-NP and CREDIBLE-CR clinical trial results?

Year: 2021

Type: article

Abstract: Cefiderocol is a novel siderophore-cephalosporin conjugate antibiotic approved for treatment of Gram-negative bacterial infections. In-vitro laboratory testing found cefiderocol to be effective against many species, including carbapenem-resistant and multidrug resistant isolates1. As part of the APEKS-NP clinical trial,2 cefiderocol was evaluated in the treatment of health-care-associated pneumonia caused largely by carbapenem-susceptible, cephalosporin-resistant, extended-spectrum β-lactamase (ESBL) producers, or carbapenem-susceptible, non-ESBL strains (referred to from hereon as susceptible).

Source: The Lancet Microbe

DOI: 10.1016/s2666-5247(21)00271-8

Authors: Jacob E Choby, Tugba Ozturk, Sarah W Satola, Jesse T Jacob, David S Weiss

Institution: Emory University

Language: English

Topic: Antibiotic Resistance in Bacteria

Subfield: Molecular Medicine

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,000